Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces promising interim results from the

Flemish biopharma company, Bioxodes, has announced promising results from the BIRCH phase 2a clinical trial of BIOX-101 to treat intracerebral haemorr...

Early neurological deterioration (END) is a forecast factor in poor outcomes in minor strokes. END's prevalence and forecast factors in minor strokes caused by small artery occlusion (SAO) are still unclear.

Source: Neuroscience & Biobehavioral Reviews

The Davos Alzheimer's Collaborative, a global initiative to prevent Alzheimer's disease and improve brain health, announced that PacBio, a leader in high─quality and highly─accurate long─read sequencing platforms,

AbstractCommon variants within TMEM106B are associated with risk for frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). The G allele of the top single nucleotide polymorphism, rs1990622, confers protection against FTLD-TDP, including genetic cases due to GRN mutations or C9orf72 hexanucleotide repeat expansions. However, the effects of interaction between TMEM106B-rs1990622 and frontotemporal dementia (FTD) mutations on disease endophenotypes in genetic FTD are unknown.This longitudinal cohort study was embedded within the GENetic Frontotemporal dementia Initiative (GENFI). We included 518 participants from 222 families [209 non-carriers; 222 presymptomatic carriers (C9orf72  = 79; GRN = 101, MAPT = 42); 87 symptomatic carriers (C9orf72 = 45; GRN = 29; MAPT = 13)] followed for up to 7 years. Using linear mixed-effects models, we examined the effects of a triple interaction between TMEM106B-rs1990622G allele dosage (additive model: 0, 1 or 2 alleles) and autosomal dominant FTD mutations with clinical status, and time from baseline on (i) grey matter volume using a voxel-based analysis; (ii) serum neurofilament light chain (NfL) levels; and (iii) cognitive and behavioural measures.Mean age of participants was 47.9 ± 13.8 years, 58.1% were female and 61% had at least one G allele. C9orf72: rs1990622G allele dosage was associated with less atrophy within the right occipital region in presymptomatic carriers at baseline, and reduced atrophy rate within putamen and caudate nucleus, right frontotemporal regions, left cingulate and bilateral insular cortices in symptomatic carriers over time; lower NfL levels in presymptomatic carriers at baseline; better executive functions and language abilities in presymptomatic carriers; and maintained overall cognitive functions and behaviour in symptomatic carriers over time. GRN: rs1990622G allele dosage was associated with reduced grey matter atrophy rate within the right temporal and occipital regions in presymptomatic carriers, and within the right frontal cortex and insula over time in symptomatic carriers; lower serum NfL levels over time in presymptomatic carriers and lower NfL levels at both baseline and over time in symptomatic carriers; and better global cognitive performance at baseline and higher attention/processing speed scores over time in symptomatic carriers. MAPT: rs1990622G allele dosage was associated with reduced grey matter atrophy rate within the right inferior frontal gyrus in symptomatic carriers, but no effects on serum NfL or cognitive/behavioural measures.TMEM106B-rs1990622G allele dosage showed protective effects on multiple endophenotypes predominantly in GRN and C9orf72 groups. Therefore, TMEM106B genotype should be assessed in clinical trials, particularly of GRN- and C9orf72-related genetic FTD, due to its modifying effects on biomarker, imaging, cognitive and clinical outcomes.

Epiminder, a pioneering medical device and information solutions company, announced that it has been granted FDA authorisation via the De Novo classification for Minder, its proprietary implantable continuous

Source: NeuroImage

Source: NeuroImage

Intracranial hypertension (IH) is a well-documented diagnosis in children but remains challenging to clinicians because patients often present with non-specific symptoms. Clinical features concerning for “red-flag signs” in headache could potentially be representative of IH, however incidence or predictive value of these features are not well-reported in children.

Intracranial hypertension (IH) is a well-documented diagnosis in children but remains challenging to clinicians because patients often present with non-specific symptoms. Clinical features concerning for “red-flag signs” in headache could potentially be representative of IH, however incidence or predictive value of these features are not well-reported in children.

Chronic subdural hematoma (CSDH) is a prevalent neurosurgical condition among elderly patients, a trend that aligns with the global aging population [1,2]. CSDH can manifest with symptoms like headache, altered consciousness, and motor dysfunction due to cerebral compression from the hematoma [1]. Burr hole craniostomy with intraoperative irrigation and subdural drainage is the standard surgical approach [1,3–5]. However, 1.3–14.0 % of patients require repeat surgeries after the initial procedure [1,3–10].

Due to the lack of long-term studies, this research aimed to explore the changes and predictors of autonomic dysfunction (AD) in people with multiple ...

Source: Neurobiology of Disease

Grey matter (GM) atrophy is associated with cognitive impairment (CI) in multiple sclerosis (MS). We aimed to investigate the predictive role of early...

J Neurosurg Spine 42:443–452, 2025

Accessing the jugular foramen (JF) surgically poses challenges due to the anatomical complexity of the region, technical intricacies, and the risk of neurovascular injuries [1]. Tumors involving the JF are rare skull base lesions, encompassing schwannomas, paragangliomas, chordomas, chondrosarcomas, and meningiomas, which are slow-growing and have the potential to compress peripheral vascular nerves, as well as exhibit invasive characteristics. Furthermore, these lesions demonstrate diverse growth patterns, either intraforaminal or with extracranial and intradural extensions, closely interrelated with significant neighboring structures such as the lower cranial nerves, carotid artery, sigmoid sinus, jugular bulb, labyrinth, fallopian canal, and upper cervical region [2,3].

Gliomas, particularly glioblastoma (GBM), remain challenging to treat and have a poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting EGFR have shown promise, but their efficacy in gliomas is not well established. This study aimed to systematically review and meta-analyze the safety and efficacy of EGFR TKIs in patients with glioma, specifically for primary and recurrent GBM.

Despite maximal safe resection followed by concurrent chemoradiation, high grade gliomas (HGGs) have a propensity for recurrence [1–3]. Furthermore, recurrent high-grade gliomas (rHGGs) are aggressive in nature and demonstrate a tendency towards radiation and chemotherapy resistance [1,2]. Therefore, managing recurrent HGGs is extremely challenging. This is exemplified by a relative lack of high-level treatment evidence in this setting [1,2].

Carriers of GBA1 gene variants exhibit a well-established elevated risk for developing synucleinopathies, particularly Parkinson's disease (PD) and dementia with Lewy bodies (DLB).[1] Genotype-phenotype analyses have consistently demonstrated correlations between specific gene variants and disease characteristics, including penetrance, progression rate, and the manifestation of non-motor symptoms such as dementia, dysautonomia, and psychosis.[1-3]

Carriers of GBA1 gene variants exhibit a well-established elevated risk for developing synucleinopathies, particularly Parkinson's disease (PD) and dementia with Lewy bodies (DLB).[1] Genotype-phenotype analyses have consistently demonstrated correlations between specific gene variants and disease characteristics, including penetrance, progression rate, and the manifestation of non-motor symptoms such as dementia, dysautonomia, and psychosis.[1-3]

The objective of this study was to delineate synaptic density alterations in multiple system atrophy (MSA) and explore its potential role as a biomark...